OBJECTIVES: to review prevalence and risk factors of febrile neutropenia in breast cancer patients received adjuvant paclitaxel treatment. METHODS: retrospective chart review of 18 breast cancer patients received 146 cycles of adjuvant paclitaxel for prevention of breast cancer recurrence during 2011 at Phramongkutklao hospital, Bangkok, Thailand  RESULTS: Average age of patient in this study was 54.6+/-10.5 years old. Paclitaxel were given to patients in 7 dosage regimens. The most common dosage regimen (62/146, 42.5%) was weekly paclitaxel 12 cycles post doxorubicin and cylcophosphamide (AC) regimen. There were 3 febrile neutropenia cases out of 18 patients who recieved 154 cycles of adjuvant paclitaxel treatment. Prevalence of febrile neutropenia in this study was 2.05%. Prevalence of neutropenia in this study was 7.5% (11 cases out of 146 treatment cycles). Dosage regimen of paclitaxel (> 100 mg/m  /cycle ) associated with neutropenia was found to associated with neutropenia. Other common adverse events found in this study were peripheral neuropathy in 9 cases (50%), nausea/vomiting 7 cases (29%) and muscle weakness 6 cases (25%).  CONCLUSIONS: Neutropenia from higher dose (>100 mg/m) of paclitaxel was common and trend to associated with febrile neutropenia in breast cancer patients treated with this drug. Closely monitoring and supportive therapy is needed in the patients recieving higher paclitaxel dose to prevent febrile nutropenia during adjuvant paclitaxel treatment.